Co-expression of Oct-4 and Nestin in human breast cancers
- First Online:
- Cite this article as:
- Liu, C., Cao, X., Zhang, Y. et al. Mol Biol Rep (2012) 39: 5875. doi:10.1007/s11033-011-1398-6
- 407 Downloads
The aim is to investigate the clinical implications of the Oct-4 and Nestin protein in human breast cancers. A total of 346 cases including 26 fresh and 320 paraffin-embedded tumor tissues were selected for characterizing the frequency of CD44+CD24− tumor cells by flow cytometry and the differential expression of the stem cell-related genes between CD44+CD24− and non-CD44+CD24− tumor cells was analyzed by PCR Array and immunofluorescence. In comparison with the non-CD44+CD24− tumor cells, the CD44+CD24−, particularly for those with high percentage of Oct-4+ and Nestin+, tumor cells had higher tumorigenicity by forming mammospheres in vitro. More importantly, 42 (13.125%) out of 320 tumor tissues were positive for Oct-4 and Nestin staining. Universal analysis and multivariate analysis revealed that the expression of Oct-4 and Nestin was associated significantly with younger age, pathogenic degrees, lymph node metastasis and triple-negative breast cancer independently (P < 0.05) as well as shorter survival (P = 0.001). Oct-4 and Nestin were important regulators of the development of breast cancer, and Oct-4 and Nestin may be used as predictors for the prognosis of breast cancers.